Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon

Stock Information for Motus GI Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Motus GI Holdings Inc.

Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
 Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro
Motus GI Announces 1-for-15 Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.